CClinicalTrials.gg
Status unknownNCT05522920Complete TESCSUpdated Aug 31, 2022

Spinal Stimulation for Chronic Complete Tetraplegia

An interventional study of Therapy with and without spinal cord stimulation in Spinal Cord Injuries, sponsored by NHS Greater Glasgow and Clyde. Status unknown. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-08-31.

Sponsored by NHS Greater Glasgow and Clyde · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Aug 2022), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is investigate the acceptability and effectiveness of transcutaneous spinal cord stimulation in people with complete high level spinal cord injury.

02

Conditions studied

  • Spinal Cord Injuries
03

In context

Spinal Cord Injuries

1,948 studies on the registry are indexed under Spinal Cord Injuries; 505 are open to participants now.

This study's planned enrollment of 12 is below the median of 24 across 1,566 interventional studies indexed under Spinal Cord Injuries.

Browse Spinal Cord Injuries studies →

Lead sponsor

NHS Greater Glasgow and Clyde is the lead sponsor of 215 studies on the registry; 39 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Willing and able to give informed consent for participation in the study
  • Aged ≥18 years
  • Injury level C3-C7, American Spinal Cord injury Association Impairment Scale (ASIA) A
  • ≥1 year post-injury
  • Medically stable, cognitively intact, and able to breathe independently
  • Able to attend all sessions two or three times per week, for 2 h sessions and assessments

Exclusion criteria

Exclusion Criteria:

  • Any implanted active metallic device including, but not limited to neurostimulators, cochlear implants, pacemakers, implantable defibrillators, or drug delivery pumps
  • Possible, suspected, or confirmed pregnancy and/or lactation
  • Recent history or fracture, contractures or pressure sore, deep vein thrombosis (DVT) or urinary tract, or other infection that may interfere with the intervention and training
  • History of epilepsy and/or seizures
  • Severe spasticity which has been unstable over the 3 months prior to enrolment and is not expected to change and/or taking varying doses of anti-spasticity medications which could not be tapered to a stable dose and are not expected to change
  • Botulinum toxin injections within 6 months of participation
  • Non-injury related neurological impairment
  • Clinically significant severe depression in spite of treatment
  • Cardiovascular disease
  • Autonomic dysreflexia that is severe, ongoing, and has required medical treatment within the past month
  • Skin conditions or allergies that may affect electrode placement
  • Do not understand English
  • Received a stem cell treatment or other treatment that could possibly promote or attenuate neuroplastic changes in spinal or cortical function, within ≥2 years of enrolment; beyond this period, they may be included, provided the treatment was conducted in an accredited facility with proper ethics and regulatory approval.
  • Involved in any other study involving stimulation of the spinal cord within 6 months of enrolment
  • Information regarding recent rehabilitation or exercise programmes that participants may currently be engaged in will be discussed with clinical staff and fully documented for each participant
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    Therapy

    Conventional physical therapy will be used with and without spinal cord stimulation to investigate improvement of upper limb function.

    Other: Therapy with and without spinal cord stimulation

Interventions

  • OtherTherapy with and without spinal cord stimulation

    Conventional therapy only will be followed with conventional therapy combined with electrical spinal cord stimulation.

06

What researchers measure

Primary outcomes

  1. Acceptance

    Whether the treatment protocol is acceptable by people with complete tetraplegia. This will be assessed using semi structured interview results of which will be analysed qualitatively to determine the number of participants who would use the therapy on an ongoing basis.

    Time frame: 26 weeks at the end of intervention

Secondary outcomes

  1. Clinical effectiveness of spinal cord stimulation using GRASSP tool

    Effectiveness of spinal cord stimulation in inducing changes in functional outcome. This will be assessed using the Graded and Redefined Assessment of Strength, Sensibility, and Prehension (GRASSP tool). The unit is based on the GRASSP measurement scale.

    Time frame: 26 and 38 weeks, at the end of intervention and at follow up respectively

  2. Neurophysiological change

    Effectiveness of spinal cord stimulation in inducing changes in Neurophysiological equivalence of volitional movement. This will be assessed using changes in amplitude in mV of transcranial magnetic stimulation.

    Time frame: 26 and 38 weeks, at the end of intervention and at follow up respectively

  3. Sensation

    Change in sensation due to the intervention. This will be assessed using change the sensory score of the International Standards for Neurological classification of SCI (ISNCSCI)

    Time frame: 26 weeks at the end of intervention

  4. Spasticity

    Changes in upper limb muscle tone using change in the Modified Ashworth Scale.

    Time frame: 26 weeks at the end of intervention

  5. Autonomic function

    Changes in autonomic function will be assessed using changes in the AUTONOMIC STANDARDS ASSESSMENT FORM of the International Spinal Cord Injury Data Set.

    Time frame: 26 weeks at the end of intervention

  6. Change in perceived health status

    The effect of the study on perceived health status of the participants will be assessed using QUALITY OF LIFE BASIC DATA SET of the International Spinal Cord Injury Data Set.

    Time frame: 26 weeks at the end of intervention

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided — The is no plan yet to share individual participant data.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 31, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05522920
Lead sponsor
NHS Greater Glasgow and Clyde
Collaborators
International Spinal Research Trust
Responsible party
Sponsor
First posted
Aug 31, 2022
Start date
Aug 2022 (estimated)
Primary completion
Jun 2024 (estimated)
Completion
Dec 2024 (estimated)
Last update
Aug 31, 2022

Study contacts

Mariel Purcell, Consultant
Contact
margaret.purcell@ggc.scot.nhs.uk
+44 141 201 2536
Bethel C Osuagwu, PhD
Contact
bethel.osuagwu@gmail.com
+44 7944142407
Mariel Purcell, Consultant
study director · NHS Greater Glasgow and Clyde

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion